{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T16:03:32Z","timestamp":1784736212434,"version":"3.55.0"},"reference-count":39,"publisher":"American Medical Association (AMA)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n Importance<\/jats:title>\n Use of piperacillin-tazobactam (TZP) as treatment for bloodstream infections (BSIs) has increased over time in Europe, as has antimicrobial resistance to TZP in some European countries.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To evaluate mortality associated with TZP-resistant BSIs in the Danish health care system.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n \n In this cohort study, data collected in near real time were obtained from Danish national health registers from November 15, 2018, through November 21, 2024. Participants were patients aged 18 years or older with monomicrobial\n Escherichia coli<\/jats:italic>\n or\n Klebsiella pneumoniae<\/jats:italic>\n BSI, restricted to the first positive (index) blood culture with a TZP-susceptibility test result during the follow-up period.\n <\/jats:p>\n <\/jats:sec>\n \n Exposures<\/jats:title>\n \n E coli<\/jats:italic>\n or\n K pneumoniae<\/jats:italic>\n BSI and a TZP susceptibility test classified as TZP resistant or TZP susceptible.\n <\/jats:p>\n <\/jats:sec>\n \n Main Outcome and Measures<\/jats:title>\n Thirty-day mortality hazard ratios (HRs) for BSIs with TZP-resistant vs TZP-susceptible bacteria were estimated from the index date (blood culture) until death, emigration, or end of the observation period. Mortality was drawn from Danish national health registers, with no restriction on in-hospital or postdischarge mortality. Univariable and multivariable models adjusted a priori for self-reported gender, age, comorbidity, year, length of hospital stay until BSI, total length of inpatient stays in the prior year, and BSI in the prior 6 months with species other than that in the index culture.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n The study population included 34\u202f379 patients (median overall age, 76 years [IQR, 66-83 years]; 51.5% male). Among 28\u202f649 patients (81.9%) with\n E coli<\/jats:italic>\n BSI, 1689 (5.9%) had a TZP-resistant BSI; among 6314 patients (18.1%) with\n K pneumoniae<\/jats:italic>\n BSI, 597 (9.5%) had a TZP-resistant BSI. There was no loss to follow-up, and about 1% of participants were right-censored by the end of the observation period (\n E coli<\/jats:italic>\n : 343 [1.2%];\n K pneumoniae<\/jats:italic>\n , 88 [1.4%]). Mortality was similar for patients with TZP-resistant and TZP-susceptible BSI after adjusting for baseline risk factors (\n E coli<\/jats:italic>\n : crude HR, 1.22 [95% CI, 1.08-1.38]; adjusted HR [AHR], 1.09 [95% CI, 0.94-1.27];\n K pneumoniae<\/jats:italic>\n : crude HR, 1.27 [95% CI, 1.05-1.52]; AHR, 1.15 [95% CI, 0.94-1.41]).\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n \n In this cohort study of patients with monomicrobial\n E coli<\/jats:italic>\n or\n K pneumoniae<\/jats:italic>\n BSI, there was no significant difference in mortality for patients with BSI caused by TZP-resistant vs TZP-susceptible bacteria after adjustment for baseline risk factors. The result is important given increasing TZP resistance in Denmark and other countries.\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2026.24366","type":"journal-article","created":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T15:30:30Z","timestamp":1784734230000},"page":"e2624366","source":"Crossref","is-referenced-by-count":0,"title":["Mortality After Piperacillin-Tazobactam\u2013Resistant vs \u2013Susceptible Bloodstream Infection"],"prefix":"10.1001","volume":"9","author":[{"given":"Erich","family":"Tusch","sequence":"first","affiliation":[{"name":"Department of Data Science and AI in Health, Statens Serum Institut, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Holzknecht","sequence":"additional","affiliation":[{"name":"Department of Bacteria, Parasites, and Fungi, Statens Serum Institut, Copenhagen, Denmark"},{"name":"Department of Clinical Microbiology, Copenhagen University Hospital\u2013Herlev and Gentofte, Herlev, Denmark"},{"name":"Department of Clinical Medicine, Copenhagen University, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikkel","family":"Lindegaard","sequence":"additional","affiliation":[{"name":"Department of Bacteria, Parasites, and Fungi, Statens Serum Institut, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rikke Thoft","family":"Nielsen","sequence":"additional","affiliation":[{"name":"Department of Data Integration and Analysis, Statens Serum Institut, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrik S.","family":"Justesen","sequence":"additional","affiliation":[{"name":"Department of Clinical Microbiology, Odense University Hospital, Odense, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirstine Kobber\u00f8e","family":"S\u00f8gaard","sequence":"additional","affiliation":[{"name":"Department of Clinical Microbiology, Aalborg University Hospital, Aalborg, Denmark"},{"name":"Department of Clinical Medicine, Aalborg University, Aalborg, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomislav Simeonov","family":"Kostyanev","sequence":"additional","affiliation":[{"name":"Department of Clinical Microbiology, Southern Denmark University Hospital, Esbjerg and Grindsted Hospital, Esbjerg, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederik Bo\u00ebtius","family":"Hertz","sequence":"additional","affiliation":[{"name":"Department of Clinical Microbiology, Copenhagen University Hospital\u2013Herlev and Gentofte, Herlev, Denmark"},{"name":"Department of Immunology & Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Pedersen","sequence":"additional","affiliation":[{"name":"Department of Clinical Microbiology, Copenhagen University Hospital\u2013Herlev and Gentofte, Herlev, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ram B.","family":"Dessau","sequence":"additional","affiliation":[{"name":"Department of Clinical Microbiology, Zealand University Hospital, Roskilde, Denmark"},{"name":"Institute of Regional Health Research, University of Southern Denmark, Odense, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sissel","family":"Skovgaard","sequence":"additional","affiliation":[{"name":"Department of Clinical Microbiology, Copenhagen University Hospital\u2013Herlev and Gentofte, Herlev, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jon Gitz","family":"Holler","sequence":"additional","affiliation":[{"name":"Department of Pulmonary and Infectious Diseases, Copenhagen University Hospital\u2013North Zealand, Hiller\u00f8d, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisbeth","family":"L\u00fctzen","sequence":"additional","affiliation":[{"name":"Department of Clinical Microbiology, Southern Denmark University Hospital, Sygehus Lilleb\u00e6lt, Vejle, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Svend","family":"Ellermann-Eriksen","sequence":"additional","affiliation":[{"name":"Department of Clinical Microbiology, Aarhus University Hospital, Aarhus, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ute Wolff","family":"S\u00f6nksen","sequence":"additional","affiliation":[{"name":"Department of Bacteria, Parasites, and Fungi, Statens Serum Institut, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Skov","sequence":"additional","affiliation":[{"name":"Epidemiological Infectious Disease Preparedness, Statens Serum Institut, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lasse Engbo","family":"Christiansen","sequence":"additional","affiliation":[{"name":"Department of Data Science and AI in Health, Statens Serum Institut, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders Rhod","family":"Larsen","sequence":"additional","affiliation":[{"name":"Department of Bacteria, Parasites, and Fungi, Statens Serum Institut, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders","family":"Hviid","sequence":"additional","affiliation":[{"name":"Department of Data Science and AI in Health, Statens Serum Institut, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anette M.","family":"Hammerum","sequence":"additional","affiliation":[{"name":"Department of Bacteria, Parasites, and Fungi, Statens Serum Institut, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Bager","sequence":"additional","affiliation":[{"name":"Department of Data Science and AI in Health, Statens Serum Institut, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2026,7,22]]},"reference":[{"issue":"1","key":"zoi260685r1","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1093\/clinids\/22.1.107","article-title":"Piperacillin\/tazobactam: a critical review of the evolving clinical literature.","volume":"22","author":"Sanders","year":"1996","journal-title":"Clin Infect Dis"},{"issue":"5","key":"zoi260685r2","doi-asserted-by":"publisher","first-page":"805","DOI":"10.2165\/00003495-199957050-00017","article-title":"Piperacillin\/tazobactam: an updated review of its use in the treatment of bacterial infections.","volume":"57","author":"Perry","year":"1999","journal-title":"Drugs"},{"issue":"3","key":"zoi260685r3","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00582-2017","article-title":"International ERS\/ESICM\/ESCMID\/ALAT guidelines for the management of hospital-acquired pneumonia and ventilator-associated pneumonia: guidelines for the management of hospital-acquired pneumonia (HAP)\/ventilator-associated pneumonia (VAP) of the European Respiratory Society (ERS), European Society of Intensive Care Medicine (ESICM), European Society of Clinical Microbiology and Infectious Diseases (ESCMID) and Asociaci\u00f3n Latinoamericana del T\u00f3rax (ALAT).","volume":"50","author":"Torres","year":"2017","journal-title":"Eur Respir J"},{"issue":"11","key":"zoi260685r10","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1136\/bmjqs-2012-001791","article-title":"A managed multidisciplinary programme on multi-resistant Klebsiella pneumoniae in a Danish university hospital.","volume":"22","author":"Andersen","year":"2013","journal-title":"BMJ Qual Saf"},{"issue":"1","key":"zoi260685r11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/jac\/dkw385","article-title":"Role of cephalosporins in the era of Clostridium difficile infection.","volume":"72","author":"Wilcox","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"zoi260685r12","doi-asserted-by":"publisher","first-page":"S14","DOI":"10.1016\/j.cmi.2023.09.001","article-title":"A systematic review on the excess health risk of antibiotic-resistant bloodstream infections for six key pathogens in Europe.","volume":"30","author":"Hassoun-Kheir","year":"2024","journal-title":"Clin Microbiol Infect"},{"key":"zoi260685r13","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.cmi.2023.10.004","article-title":"Synthesizing pathogen- and infection-specific estimates of the burden of antimicrobial resistance in Europe for health-technology assessment: gaps, heterogeneity, and bias.","volume":"30","author":"Robotham","year":"2024","journal-title":"Clin Microbiol Infect"},{"issue":"7","key":"zoi260685r14","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1177\/1403494810387965","article-title":"The Danish Civil Registration System.","volume":"39","author":"Pedersen","year":"2011","journal-title":"Scand J Public Health"},{"key":"zoi260685r15","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2024.1502739","article-title":"Mandatory surveillance of bacteremia conducted by automated monitoring.","volume":"12","author":"M\u00f8lbak","year":"2024","journal-title":"Front Public Health"},{"key":"zoi260685r16","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2024.1502893","article-title":"The increasing incidence and mortality of bacteremia in Denmark from 2010 to 2022: a population-based nationwide cohort study.","volume":"12","author":"Dessau","year":"2024","journal-title":"Front Public Health"},{"key":"zoi260685r17","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.ijmedinf.2016.09.001","article-title":"MiBAlert\u2014a new information tool to fight multidrug-resistant bacteria in the hospital setting.","volume":"95","author":"Olesen","year":"2016","journal-title":"Int J Med Inform"},{"issue":"7","key":"zoi260685r18","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1111\/apm.13140","article-title":"Electronic reporting of diagnostic laboratory test results from all healthcare sectors is a cornerstone of national preparedness and control of COVID-19 in Denmark.","volume":"129","author":"Sch\u00f8nning","year":"2021","journal-title":"APMIS"},{"issue":"1","key":"zoi260685r19","doi-asserted-by":"publisher","first-page":"20667","DOI":"10.2807\/1560-7917.ES2014.19.1.20667","article-title":"The Danish Microbiology Database (MiBa) 2010 to 2013.","volume":"19","author":"Voldstedlund","year":"2014","journal-title":"Euro Surveill"},{"key":"zoi260685r21","doi-asserted-by":"publisher","first-page":"449","DOI":"10.2147\/CLEP.S91125","article-title":"The Danish National Patient Registry: a review of content, data quality, and research potential.","volume":"7","author":"Schmidt","year":"2015","journal-title":"Clin Epidemiol"},{"key":"zoi260685r22","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.ijmedinf.2016.08.003","article-title":"The development and use of a new methodology to reconstruct courses of admission and ambulatory care based on the Danish National Patient Registry.","volume":"95","author":"Gubbels","year":"2016","journal-title":"Int J Med Inform"},{"issue":"7","key":"zoi260685r23","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1177\/1403494810394717","article-title":"The Danish National Prescription Registry.","volume":"39","author":"Kildemoes","year":"2011","journal-title":"Scand J Public Health"},{"key":"zoi260685r24","doi-asserted-by":"publisher","first-page":"783","DOI":"10.2147\/CLEP.S487838","article-title":"The Danish National Hospital Medication Register: a resource for pharmacoepidemiology.","volume":"16","author":"Rosenkrantz","year":"2024","journal-title":"Clin Epidemiol"},{"issue":"11","key":"zoi260685r26","doi-asserted-by":"publisher","DOI":"10.1002\/pds.70054","article-title":"Data resource profile: the Danish National Hospital Medicine Register.","volume":"33","author":"Andersen","year":"2024","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"7624","key":"zoi260685r28","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1136\/bmj.39335.541782.AD","article-title":"Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies.","volume":"335","author":"von Elm","year":"2007","journal-title":"BMJ"},{"issue":"6","key":"zoi260685r29","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1093\/aje\/kwq433","article-title":"Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries.","volume":"173","author":"Quan","year":"2011","journal-title":"Am J Epidemiol"},{"issue":"21","key":"zoi260685r30","doi-asserted-by":"publisher","first-page":"2323","DOI":"10.1001\/jama.2009.1754","article-title":"International study of the prevalence and outcomes of infection in intensive care units.","volume":"302","author":"Vincent","year":"2009","journal-title":"JAMA"},{"issue":"2","key":"zoi260685r33","doi-asserted-by":"publisher","DOI":"10.1093\/jacamr\/dlad041","article-title":"Association between piperacillin\/tazobactam MIC and survival among hospitalized patients with Enterobacterales infections: retrospective cohort analysis of electronic health records from 161 US hospitals.","volume":"5","author":"Strich","year":"2023","journal-title":"JAC Antimicrob Resist"},{"key":"zoi260685r34","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2022.101781","article-title":"Antimicrobial resistance and mortality following E. coli bacteremia.","volume":"56","author":"Daneman","year":"2022","journal-title":"EClinicalMedicine"},{"issue":"2","key":"zoi260685r35","doi-asserted-by":"publisher","first-page":"e00047","DOI":"10.1128\/CMR.00047-19","article-title":"Epidemiology of \u00df-Lactamase-Producing Pathogens.","volume":"33","author":"Bush","year":"2020","journal-title":"Clin Microbiol Rev"},{"issue":"10","key":"zoi260685r36","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1001\/jama.2018.12163","article-title":"Effect of piperacillin-tazobactam vs meropenem on 30-day mortality for patients with E coli or Klebsiella pneumoniae bloodstream infection and ceftriaxone resistance: a randomized clinical trial.","volume":"320","author":"Harris","year":"2018","journal-title":"JAMA"},{"issue":"11","key":"zoi260685r37","doi-asserted-by":"publisher","first-page":"e3842","DOI":"10.1093\/cid\/ciaa1479","article-title":"Association between minimum inhibitory concentration, beta-lactamase genes and mortality for patients treated with piperacillin\/tazobactam or meropenem from the MERINO Study.","volume":"73","author":"Henderson","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"2","key":"zoi260685r39","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/S1473-3099(16)30257-2","article-title":"Occurrence of carbapenemase-producing Klebsiella pneumoniae and Escherichia coli in the European Survey of Carbapenemase-Producing Enterobacteriaceae (EuSCAPE): a prospective, multinational study.","volume":"17","author":"Grundmann","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"zoi260685r4","unstructured":"European Centre for Disease Prevention and Control. Antimicrobial resistance in the EU\/EEA (EARS-Net)\u2014annual epidemiological report for 2024. November 18, 2024. Accessed November 3, 2025. https:\/\/www.ecdc.europa.eu\/en\/publications-data\/antimicrobial-resistance-eueea-ears-net-annual-epidemiological-report-2024"},{"key":"zoi260685r5","unstructured":"Public Health Agency of Sweden and Swedish Veterinary Agency. Sales of antibiotics and occurrence of antibiotic resistance in Sweden. 2024. Accessed December 26, 2025. https:\/\/www.folkhalsomyndigheten.se\/publikationer-och-material\/publikationsarkiv\/s\/swedres-svarm-2024\/"},{"key":"zoi260685r6","unstructured":"Norwegian Institute of Public Health and University Hospital of North Norway. Norsk overv\u00e5kingssystem for antibiotikaresistens hos mikrober (NORM) og Norsk overv\u00e5kingsprogram for antibiotikaresistens i mikrober fra f\u00f4r, dyr og n\u00e6ringsmidler (NORM-VET). 2023. Accessed December 26, 2025. https:\/\/www.unn.no\/fag-og-forskning\/norm-norsk-overvakingssystem-for-antibiotikaresistens-hos-mikrober#rapporter"},{"key":"zoi260685r7","unstructured":"Danish Integrated Antimicrobial Resistance Monitoring and Research Programme. Danish programme for surveillance of antimicrobial consumption and resistance in bacteria from food animals, food and humans. DANMAP report 2024. Accessed October 30, 2025. https:\/\/www.danmap.org\/reports\/2024"},{"key":"zoi260685r8","unstructured":"Danish Integrated Antimicrobial Resistance Monitoring and Research Programme. Danish programme for surveillance of antimicrobial consumption and resistance in bacteria from food animals, food and humans. DANMAP report 2019. Accessed November 3, 2025. https:\/\/www.danmap.org\/reports\/2019"},{"key":"zoi260685r9","unstructured":"Sundhedsstyrelsen (Danish Health and Medicine Authority). Guidelines on prescribing antibiotics 2013 (for physicians and others in Denmark). November 15, 2012. Accessed October 28, 2025. https:\/\/www.sst.dk\/da\/udgivelser\/2012\/Vejledning-om-ordination-af-antibiotika---Til-landets-laeger"},{"key":"zoi260685r20","unstructured":"Danish Integrated Antimicrobial Resistance Monitoring and Research Programme. MiBa, the Danish Microbiology Database\u2014now prepared for use in national AMR-surveillance. Danish programme for surveillance of antimicrobial consumption and resistance in bacteria from food animals, food and humans. DANMAP report 2018: text box 8.1, pp 118-121. Accessed September 24, 2025. https:\/\/www.danmap.org\/reports\/2018"},{"key":"zoi260685r25","unstructured":"Danish Health Data Authority. Data declaration (report) for the Danish National Hospital Medicine Register, June 2023. Accessed August 11, 2025. https:\/\/sundhedsdatastyrelsen.dk\/indberetning\/sygehusmedicinregisteret"},{"key":"zoi260685r27","unstructured":"Danish Ministry of Health. Act on research ethics review of health research projects (Consolidated Act No. 1338 of 1 September 2020). 2020. Accessed June 25, 2026. https:\/\/www.retsinformation.dk\/eli\/lta\/2020\/1338"},{"key":"zoi260685r31","unstructured":"R: A Language and Environment for Statistical Computing. Version 4.4.1. R Project for Statistical Computing; 2012. Accessed June 11, 2026. https:\/\/www.R-project.org\/"},{"key":"zoi260685r32","unstructured":"survival: a package for survival analysis in R. Version 3.8-6. R Project for Statistical Computing; 2026. Accessed June 11, 2026. https:\/\/CRAN.R-project.org\/package=survival"},{"key":"zoi260685r38","unstructured":"European Centre for Disease Prevention and Control. Surveillance of antimicrobial resistance in Europe, 2022 data. November 17, 2023. Accessed November 3, 2026. https:\/\/www.ecdc.europa.eu\/en\/publications-data\/surveillance-antimicrobial-resistance-europe-2022-data"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2851934\/tusch_2026_oi_260685_1784140102.82888.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T15:30:33Z","timestamp":1784734233000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2851934"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,22]]},"references-count":39,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2026.24366","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,22]]}}}